Perigo (PRGO) Q1 2026: Store Brand OTC Share Surges 270bps, Offsetting Market Headwinds
Perigo’s first quarter highlighted robust market share gains in U.S. store brand OTC, even as macro and category softness drove a top-line decline. The company’s 3S plan—stabilize, streamline, and strengthen—showed clear operational progress, but transitory headwinds in cough, cold, and retailer inventory pressured results. Management reaffirmed full-year guidance, citing second-half weighted drivers and underlying momentum in core brands and innovation.
Summary
- Store Brand Outperformance: U.S. OTC share gains outpaced category, reflecting contract wins and demand generation.
- Streamlining Delivers: Portfolio simplification and cost initiatives countered external volatility.
- Second-Half Leverage: Innovation, distribution, and cost savings expected to drive H2 recovery.
Business Overview
Perigo is a global consumer self-care company, generating revenue primarily from over-the-counter (OTC) store brand and branded health products, specialty care, and infant formula. Its major segments—Self-Care, Specialty Care, and Infant Formula—span U.S. and European markets, with a focus on private label partnerships and leading brands in categories like allergy, pain, digestive health, and women’s health.
Performance Analysis
First quarter results reflected a challenging consumer health backdrop, with net sales declining as softer cough and cold incidence and retailer inventory destocking drove an 8.3% core sales drop. The self-care segment bore the brunt, pressured by volume headwinds and unfavorable mix, while specialty care partially offset with gains in women’s health. Infant formula delivered modest growth, buoyed by contract manufacturing, though branded volumes faced tough comps.
Gross margin contracted due to lower volumes and lingering manufacturing cost carryover, with both core and all-in margins down sequentially. Operational enhancement programs delivered $7 million in cost savings, and tariff recovery alongside lower tax rates supported EPS above expectations. Cash flow was negative, in line with seasonal patterns, and proceeds from the dermacosmetics divestiture are earmarked for debt reduction.
- Volume Share Acceleration: Store brand OTC volume share jumped 270 basis points, with six of seven categories gaining ground.
- Category Weakness: Cough and cold softness and destocking accounted for nearly two-thirds of the sales decline.
- Cost Controls Cushion: Operational savings and tariff recovery offset some margin pressure, with further benefits expected as the year progresses.
Despite headline softness, the business demonstrated underlying operational strength, setting up for a second-half recovery as transitory headwinds abate and growth initiatives scale.
Executive Commentary
"Our stabilization efforts have turned share losses in U.S. store brand OTC into a 100 basis point improvement in volume share during the quarter, six of seven categories gaining share. To further dimensionalize our performance, we have gained 270 basis points of U.S. store brand OTC volume share in the first quarter alone."
Patrick Lockwood-Taylor, President & Chief Executive Officer
"Core adjusted gross margin declined 160 basis points to 39.2%, primarily due to lower sales volumes, manufacturing volume headwinds, and mix. These pressures were partially offset by the net recognition of tariff recovery and favorable foreign exchange."
Eduardo Bezerra, Chief Financial Officer
Strategic Positioning
1. 3S Plan Execution
Perigo’s 3S plan—stabilize, streamline, and strengthen—anchors its transformation. Stabilization was evident in broad-based share gains and improved service levels, while streamlining advanced with the dermacosmetics divestiture and ongoing reviews of infant formula and oral care. The strengthening pillar saw a shift to a category-led model, focusing resources on scalable brands and innovation.
2. Store Brand Differentiation
Perigo is leveraging its scale and retailer relationships to elevate store brand OTC penetration, using national-brand caliber marketing and demand generation. This dual approach—winning more contracts and driving store brand category share—delivered a “double win” in volume and value share, especially in allergy, pain, digestive health, and nicotine replacement therapy.
3. Innovation and Geographic Expansion
Consumer-centric innovation and targeted geographic expansion are central growth engines. The 360-degree innovation model brings new claims and formulations to both branded and store brand lines, expanding the addressable market and enabling faster payback on new launches. Only 5% of global households are currently served, signaling a long runway for expansion.
4. Cost Discipline and Capital Allocation
Operational enhancement programs are on track to deliver $60–80 million in annual savings, with further upside in 2027. Proceeds from asset sales are prioritized for debt reduction, and capital allocation remains balanced between growth investments and shareholder returns, with the board monitoring dividend policy quarterly.
5. Digital and Channel Execution
E-commerce is emerging as a high-growth channel, with women’s health categories up nearly 30% online in Q1. Perigo sees opportunity to improve store brand visibility and competitive takeaway on digital platforms, especially as value-seeking consumers migrate online.
Key Considerations
This quarter underscored Perigo’s ability to gain share and execute cost discipline amid external volatility, but also highlighted the reliance on second-half recovery and category normalization. Investors should weigh the following:
Key Considerations:
- Share Momentum Outpaces Category: Store brand OTC share gains were broad-based, with standout performance in nicotine replacement therapy and allergy.
- Transitory Headwinds Remain: Cough and cold softness and retailer destocking are expected to ease, but timing is uncertain.
- Second-Half Weighted Drivers: Innovation launches, distribution gains, and cost savings are concentrated in H2, amplifying execution risk if macro softness persists.
- Portfolio Simplification Ongoing: Strategic reviews of infant formula and oral care could reshape segment mix and capital allocation priorities.
- Cost Inflation and Pricing: Middle East-driven inflation is manageable for now, but Perigo is actively evaluating pricing actions if commodity pressures intensify.
Risks
Perigo’s outlook is tethered to a second-half rebound in category demand and retailer restocking, both of which remain exposed to macroeconomic uncertainty, especially in Europe. Execution risk is elevated, as innovation and cost savings must land on schedule to offset continued margin pressure. Geopolitical instability and potential for further inflation could challenge cost structure and consumer demand, while ongoing portfolio reviews introduce uncertainty to segment performance and capital allocation.
Forward Outlook
For Q2 2026, Perigo guided to:
- Continued category softness with gradual improvement in cough and cold expected as seasonal patterns normalize
- Incremental benefits from innovation, distribution, and cost programs ramping through Q2 and into H2
For full-year 2026, management reaffirmed guidance:
- Second-half weighted earnings and sales, with 65–70% of core adjusted EPS expected in H2
- Transitory manufacturing headwinds (estimated $0.60 EPS impact) expected to lap by year-end
Management highlighted several factors supporting guidance:
- Majority of innovation, distribution, and cost benefits are back-half loaded and already underway
- Retailer inventory normalization and category demand recovery are assumed, but guidance incorporates a wide range of outcomes
Takeaways
The big picture for investors is a company gaining competitive ground and executing on cost discipline, but still reliant on external recovery for margin expansion and top-line growth.
- Share Gains Signal Competitive Strength: Broad-based OTC share gains and contract wins point to execution strength and retailer partnership depth.
- Margin Recovery Hinges on H2: Operational savings and innovation are critical, but must overcome persistent macro and category headwinds.
- Watch for Portfolio Moves: Progress on infant formula and oral care reviews, along with cost discipline and digital execution, will be key for future quarters.
Conclusion
Perigo’s Q1 2026 results showcase operational resilience and market share momentum, even as external headwinds pressured sales and margins. With a second-half weighted recovery and key initiatives underway, the company’s trajectory will be defined by its ability to convert share gains and innovation into sustained growth and margin expansion.
Industry Read-Through
Perigo’s results highlight the defensive strength of store brand OTC in a volatile consumer health market, with value-seeking behavior and contract wins driving share gains even as overall category demand softens. Retailer inventory destocking and cough/cold volatility are sector-wide issues, suggesting similar near-term pressures for peers. Digital channel execution and demand generation are emerging as differentiators, with e-commerce growth in women’s health and OTC categories likely to be a broader industry theme. Portfolio simplification and cost discipline are increasingly critical, as manufacturers and suppliers seek to offset inflation and macro uncertainty through operational agility and focused investment.